Search research articles
Contact Us
Filters
Showing results (1-10 of 4) with videos related to
Page
of 1
Sort By:
Clinical Advances in Hematology & Oncology : H&O
|
April 9, 2016
Programmed death 1 immune checkpoint inhibitors
Meghna S Trivedi, Brianna Hoffner, Jennifer L Winkelmann, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
March 19, 2005
Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations
Jennifer F Tseng, Christopher G Willett, Carlos Fernandez-del Castillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 26, 2009
Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors
Dana Rathkopf, Mark A Dickson, Darren R Feldman, et al.
Cancer Chemotherapy and Pharmacology
|
February 13, 2015
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors
David M Hyman, Alexandra E Snyder, Richard D Carvajal, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 4) with videos related to
Sort By:
Page
of 1
Clinical Advances in Hematology & Oncology : H&O
|
April 9, 2016
Programmed death 1 immune checkpoint inhibitors
Meghna S Trivedi, Brianna Hoffner, Jennifer L Winkelmann, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
March 19, 2005
Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations
Jennifer F Tseng, Christopher G Willett, Carlos Fernandez-del Castillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 26, 2009
Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors
Dana Rathkopf, Mark A Dickson, Darren R Feldman, et al.
Cancer Chemotherapy and Pharmacology
|
February 13, 2015
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors
David M Hyman, Alexandra E Snyder, Richard D Carvajal, et al.
Page
of 1